Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock — Gordon R. Bernard (2013) | RDL Network
Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock
Article 2013 en
Authors
GB
Gordon R. Bernard
BF
Bruno François
JM
Jean-Paul Mira
Abstract
1 min read
AZD9773 rapidly and efficiently decreased plasma tumor necrosis factor-α concentration in patients with severe sepsis/septic shock, but this effect did not translate into clinical benefit.
Andrew J. H. Simpson, Michael D. Smith, Gerrit Jan Weverling, Yupin Suputtamongkol, Brian Angus, Wipada Chaowagul, Sir Nicholas White, Sander J. H. van Deventer, Jan M. Prins
R. Phillip Dellinger, Jean Carlet, Henry Masur, Herwig Gerlach, Thierry Calandra, Jonathan Cohen, Juan Gea‐Banacloche, Didier Keh, John C. Marshall, Margaret M. Parker, Graham Ramsay, Janice L. Zimmerman, Jean Louis Vincent, Mitchell M. Levy
Fabio Silvio Taccone, Pierre‐François Laterre, Herbert Spapen, Thierry Dugernier, Isabelle Delattre, Brice Layeux, Daniel De Backer, Xavier Wittebole, Pierre Wallemacq, Jean Louis Vincent, Frédérique Jacobs
Discussion(0)
No comments yet. Be the first to comment.